The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Study Rationale:
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure... -
Access to Data and Biospecimens, 2014Analysis of Circulating Brain-Enriched microRNA as Biomarkers for Parkinson’s Disease
Study Rationale:
Early detection of neurodegenerative diseases can lead to more effective therapeutic intervention. DiamiR proposes a diagnostic approach based on analysis of... -
Research Grant, 2013Virtual Research Visits
Objective/Rationale:
The Michael J. Fox Foundation’s Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson’s disease in clinical trials... -
Rapid Response Innovation Awards, 2010Increasing Endogenous Neurogenesis Using Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease
Objective/Rationale:
We will test a locally produced brain chemical that increases the generation of new neurons to replace the damaged neurons in Parkinson disease (PD). The production of this... -
Therapeutics Development Initiative, 2006Evaluation of the Neuroprotective Peptide NAPVSIPQ in Models of Parkinson's Disease
Parkinson's disease is characterized by the selective loss of dopamine neurons, which leads to reduced control of voluntary locomotor activities. The cause of this degeneration is unknown; however...
-
Community Fast Track, 2004The role of nociceptin/orphanin FQ in regulation of motor behavior and induction of parkinsonism
Nociceptin/orphanin FQ (N/OFQ) is an opioid-like neuropeptide discovered in the mid 90's, which activates a G-protein coupled receptor, the NOP receptor. N/OFQ and its receptor are diffusely expressed...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.